Business Description
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
Business History
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 1.88
Total Equity: $8.24B
Shares: 200,000,000
Total Debt: $2.54B
Cash: $110.60M
EBITDA: $1.05B
Total Debt: $2.54B
Cash: $110.60M
Revenue: $4.09B
Revenue: $4.09B
Revenue: $4.09B
Total Equity: $8.24B
Tax Rate: 33.8%
Equity: $8.24B
Total Debt: $2.54B
Cash: $110.60M
Current Liabilities: $1.11B
Long-Term Debt: $2.46B
Total Debt: $2.54B
Total Equity: $8.24B
Shares: 200,000,000
Shares: 200,000,000
CapEx: -$362.40M
Shares: 200,000,000
Stock Price: $71.02
Net Income: $374.90M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 6:48pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.9B | $3.3B | $3.6B | $3.9B | $4.1B |
| Cost of Revenue | $966.7M | $1.2B | $1.2B | $1.3B | $1.6B |
| Gross Profit | $2.0B | $2.1B | $2.4B | $2.6B | $2.5B |
| Operating Expenses | $1.5B | $1.6B | $1.8B | $1.9B | $1.8B |
| Operating Income | $505.8M | $507.6M | $533.1M | $705.7M | $682.9M |
| Net Income | $2.9B | $385.8M | $294.2M | $392.3M | $374.9M |
| EBITDA | $823.9M | $878.7M | $885.9M | $1.1B | $1.1B |
| EPS | $59.73 | $1.96 | $1.49 | $1.97 | $1.88 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 6:48pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $95.9M | $138.2M | $120.8M | $107.6M | $110.6M |
| Total Current Assets | $1.5B | $1.5B | $1.7B | $2.0B | $2.1B |
| Total Assets | $9.6B | $11.5B | $11.7B | $12.3B | $12.4B |
| Current Liabilities | $732.1M | $1.3B | $969.0M | $1.0B | $1.1B |
| Long-Term Debt | $1.4B | $2.3B | $2.5B | $2.5B | $2.5B |
| Total Liabilities | $2.7B | $4.3B | $4.1B | $4.2B | $4.2B |
| Total Equity | $6.9B | $7.2B | $7.6B | $8.1B | $8.2B |
| Retained Earnings | $6.2B | $6.6B | $6.9B | $7.3B | $7.6B |
Cash Flow (Annual)
Last updated: Jun 21, 2026 6:48pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $738.6M | $692.4M | $607.5M | $709.3M | $796.1M |
| Capital Expenditure | -$214.4M | -$242.0M | -$392.5M | -$421.2M | -$362.4M |
| Free Cash Flow | $524.2M | $450.4M | $215.0M | $288.1M | $433.7M |
| Acquisitions (net) | $0 | -$1.6B | -$56.5M | -$343.4M | -$10.5M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$24.8M | -$78.5M | $0 | $0 | -$290.1M |
| Net Change in Cash | -$20.5M | $42.3M | -$17.7M | -$13.2M | $2.9M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 8:05am (1h ago)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$4.3B $4.3B – $4.3B
|
$4.5B $4.5B – $4.5B
|
$4.7B $4.7B – $4.7B
|
$5.0B $5.0B – $5.0B
|
| EBITDA |
$1.1B $1.1B – $1.1B
|
$1.2B $1.2B – $1.2B
|
$1.3B $1.3B – $1.3B
|
$1.3B $1.3B – $1.3B
|
| Net Income |
$924.7M $915.7M – $933.7M
|
$999.3M $982.3M – $1.0B
|
$1.1B $910.8M – $1.2B
|
$1.2B $1.2B – $1.2B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 6:48pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +13.2% | +8.6% | +8.4% | +5.1% |
| Gross Profit Growth | +9.4% | +10.2% | +10.1% | -4.3% |
| Operating Income Growth | +0.4% | +5.0% | +32.4% | -3.2% |
| Net Income Growth | -86.9% | -23.7% | +33.3% | -4.4% |
| EBITDA Growth | +6.7% | +0.8% | +21.0% | -1.7% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 8:05am (1h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-01 | Rosebrough Walter M Jr | M-Exempt | 832.00 | $0.00 | $0 |
| 2026-01-03 | Rosebrough Walter M Jr | A-Award | 832.00 | $0.00 | $0 |
| 2026-04-01 | Rosebrough Walter M Jr | M-Exempt | 832.00 | $0.00 | $0 |
| 2026-04-01 | WEISS ROBERT S | M-Exempt | 3,654.00 | $0.00 | $0 |
| 2026-04-01 | WEISS ROBERT S | A-Award | 3,779.00 | $0.00 | $0 |
| 2026-04-01 | WEISS ROBERT S | M-Exempt | 3,654.00 | $0.00 | $0 |
| 2026-04-01 | Rivas Maria | A-Award | 3,779.00 | $0.00 | $0 |
| 2026-04-01 | Rivas Maria | M-Exempt | 3,322.00 | $0.00 | $0 |
| 2026-04-01 | Rivas Maria | M-Exempt | 3,322.00 | $0.00 | $0 |
| 2026-04-01 | Jay Colleen | M-Exempt | 3,322.00 | $0.00 | $0 |
| 2026-04-01 | Jay Colleen | A-Award | 4,157.00 | $0.00 | $0 |
| 2026-04-01 | Jay Colleen | M-Exempt | 3,322.00 | $0.00 | $0 |
| 2026-04-01 | Carbone Barbara | A-Award | 3,779.00 | $0.00 | $0 |
| 2026-04-01 | Carbone Barbara | M-Exempt | 3,050.00 | $0.00 | $0 |
| 2026-04-01 | Carbone Barbara | M-Exempt | 3,050.00 | $0.00 | $0 |
| 2026-04-01 | Rosebrough Walter M Jr | A-Award | 3,779.00 | $0.00 | $0 |
| 2026-04-01 | MADDEN TERESA S | M-Exempt | 3,322.00 | $0.00 | $0 |
| 2026-04-01 | MADDEN TERESA S | A-Award | 3,779.00 | $0.00 | $0 |
| 2026-04-01 | MADDEN TERESA S | M-Exempt | 3,322.00 | $0.00 | $0 |
| 2026-04-01 | Lucchese Cynthia L | M-Exempt | 3,322.00 | $0.00 | $0 |
Dividend History (Last 20)
Last updated: Jun 21, 2026 6:48pm (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2023-07-26 | $0.03 | 2023-07-12 | 2023-07-27 | 2023-08-11 |
| 2023-01-20 | $0.03 | 2022-12-14 | 2023-01-23 | 2023-02-10 |
| 2022-07-26 | $0.03 | 2022-07-13 | 2022-07-27 | 2022-08-11 |
| 2022-01-20 | $0.03 | 2021-12-08 | 2022-01-21 | 2022-02-09 |
| 2021-07-26 | $0.03 | 2021-07-14 | 2021-07-27 | 2021-08-11 |
| 2021-01-21 | $0.03 | 2021-01-07 | 2021-01-22 | 2021-02-09 |
| 2020-07-22 | $0.03 | 2020-07-09 | 2020-07-23 | 2020-08-07 |
| 2020-01-22 | $0.03 | 2020-01-07 | 2020-01-23 | 2020-02-10 |
| 2019-07-22 | $0.03 | 2019-07-10 | 2019-07-23 | 2019-08-07 |
| 2019-01-18 | $0.03 | 2019-01-07 | 2019-01-22 | 2019-02-08 |
| 2018-07-20 | $0.03 | 2018-07-12 | 2018-07-23 | 2018-08-07 |
| 2018-01-22 | $0.03 | 2017-12-12 | 2018-01-23 | 2018-02-09 |
| 2017-07-19 | $0.03 | 2017-07-07 | 2017-07-21 | 2017-08-07 |
| 2017-01-19 | $0.03 | 2017-01-06 | 2017-01-23 | 2017-02-09 |
| 2016-07-20 | $0.03 | 2016-07-08 | 2016-07-22 | 2016-08-05 |
| 2016-01-20 | $0.03 | 2016-01-08 | 2016-01-22 | 2016-02-09 |
| 2015-07-22 | $0.03 | 2015-07-10 | 2015-07-24 | 2015-08-06 |
| 2015-01-21 | $0.03 | 2015-01-09 | 2015-01-23 | 2015-02-09 |
| 2014-07-22 | $0.03 | 2014-07-10 | 2014-07-24 | 2014-08-06 |
| 2014-01-22 | $0.03 | 2014-01-09 | 2014-01-24 | 2014-02-07 |
Narrative Economics
market-narrative step).